Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568770 | 0.91 | PPARA (0.51) | TDP1MAPK1L3MBTL1TSHRCYP2D6 | |
| SCHEMBL18067905 | 0.87 | MAPK1 (0.62) | TDP1MAPK1L3MBTL1TSHRGALR3 | |
| SCHEMBL28032739 | 0.86 | TAAR1 (0.58) | TDP1MAPK1L3MBTL1TSHRGALR3 | |
| SCHEMBL10235891 | 0.84 | CYP2D6 (0.51) | TDP1MAPK1L3MBTL1TSHRCYP2D6 | |
| SCHEMBL327462 | 0.83 | PPARA (0.46) | CYP2D6PPARGPPARANR1H4 | |
| SCHEMBL2207505 | 0.83 | CSF3R (0.48) | TDP1MAPK1L3MBTL1TSHRCYP2D6 | |
| SCHEMBL14382693 | 0.83 | CYP2D6 (0.57) | TSHRCYP2D6PPARGPPARACNR1 | |
| 3-Propoxy-1-Isopentoxybenzene SCHEMBL2839921 | 0.83 | KMT2A (0.51) | TDP1MAPK1L3MBTL1TSHRGALR3 | |
| 1,3-Diisopentoxybenzene SCHEMBL2846359 | 0.82 | TDP1 (0.57) | TDP1MAPK1L3MBTL1TSHRGALR3 | |
| SCHEMBL19553486 | 0.82 | TDP1 (0.50) | TDP1MAPK1L3MBTL1TSHRGALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127585-A1 | DESIGN AND OPTIMIZATION OF TYPE IV BRAF INHIBITORS FOR THE TREATMENT OF MELANOMA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-28 | — | — | US | disclosed |
| US-11162083-B2 | Peptide based inhibitors of Raf kinase protein dimerization and kinase activity | UNIVERSITY OF SOUTH CAROLINA (US) | 2021-11-02 | — | — | US | disclosed |
| EP-2091955-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | Acucela, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11162083-B2 | Peptide based inhibitors of Raf kinase protein dimerization and kinase activity | BRAF, RAF1, ARAF | TDP1 900/4885MAPK1 78/4885L3MBTL1 933/4885 |
| US-20220127585-A1 | DESIGN AND OPTIMIZATION OF TYPE IV BRAF INHIBITORS FOR THE TREATMENT OF MELANOMA | BRAF, RNGTT, BCDIN3D | TDP1 1619/4885MAPK1 1091/4885L3MBTL1 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.